Intra-Cellular Therapies Submits Supplemental New Drug Application for CAPLYTA
On December 3, 2024, Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) as adjunctive therapy to antidepressants. This submission follows positive results from Studies 501 and 502, showcasing CAPLYTA’s robust […]
More Stories
Weather, Power, and Water Issues Persist in Los Angeles’ Eaton Fire Area
By Beige Luciano-Adams LOS ANGELES—Residents eager to return home and survey vast damage wrought by the Eaton Canyon Fire in...
Titanium Transportation Group (CVE:TTR) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Titanium Transportation Group Inc. (CVE:TTR – Get Free Report)’s share price passed below its 50 day moving average during trading...
Invesco Aerospace & Defense ETF (NYSEARCA:PPA) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Invesco Aerospace & Defense ETF (NYSEARCA:PPA – Get Free Report) shares crossed below its fifty day moving average during trading...
ImmuPharma (LON:IMM) Shares Up 4.9% – What’s Next?
ImmuPharma plc (LON:IMM – Get Free Report)’s share price shot up 4.9% during mid-day trading on Saturday . The company...
Omineca Mining and Metals (CVE:OMM) Stock Price Down 15.4% – Here’s Why
Omineca Mining and Metals Ltd. (CVE:OMM – Get Free Report)’s stock price traded down 15.4% on Saturday . The company...
China Shenhua Energy (OTCMKTS:CSUAY) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Shares of China Shenhua Energy Company Limited (OTCMKTS:CSUAY – Get Free Report) passed below its 50 day moving average during...